Is Wegovy better than or the same as Zepbound?
How do Zepbound and Wegovy compare, and what is the difference?
They are not the same drug. Wegovy is semaglutide from Novo Nordisk, and Zepbound is tirzepatide from Eli Lilly. Both are approved for long-term weight management. In SURMOUNT-5, the only trial that compared them directly, adults on tirzepatide lost 20.2% of their body weight at 72 weeks, compared with 13.7% on semaglutide.[1][2][3]
Wegovy vs Zepbound at a glance
Prices checked October 3, 2026.
| Attribute | HIGHLIGHTED Wegovysemaglutide | Zepbound tirzepatide |
|---|---|---|
| Active ingredient | semaglutide | tirzepatide |
| Manufacturer | Novo Nordisk | Eli Lilly |
| Drug class | GLP-1 receptor agonist | Dual GIP / GLP-1 receptor agonist |
| FDA approved | June 2021 | November 2023 |
| Indication | Chronic weight management (BMI ≥ 30, or ≥ 27 with comorbidity; ages 12+ with obesity). Also lowers heart risk in adults with heart disease, and treats MASH[2] | Chronic weight management (adults) and moderate to severe obstructive sleep apnea in adults with obesity[3] |
| Dose schedule | Subcutaneous injection · Once weekly[2] | Subcutaneous injection · Once weekly[3] |
| Available doses | 0.25 mg · 0.5 mg · 1 mg · 1.7 mg · 2.4 mg · 7.2 mg[2] | 2.5 mg · 5 mg · 7.5 mg · 10 mg · 12.5 mg · 15 mg[3] |
| Mechanism | Wegovy is the same molecule as Ozempic, semaglutide, titrated to a higher 2.4 mg maintenance dose. It binds the GLP-1 receptor, augmenting glucose-dependent insulin secretion, suppressing glucagon, slowing gastric emptying, and reducing appetite via central nervous system pathways. | Tirzepatide is a first-in-class single molecule that activates both the GIP and GLP-1 receptors. The dual incretin action slows gastric emptying and reduces appetite via central nervous system pathways while improving glucose handling. It produces larger average weight loss than single GLP-1 agonists in its obesity trials. |
| Common side effects | Nausea (44%), diarrhea (30%), and vomiting (24%) are more frequent than at Ozempic doses[2] | Nausea (25 to 29%), diarrhea (19 to 23%), vomiting (8 to 13%) at 5 mg to 15 mg. Most reports came during dose escalation[3] |
| Cost range | List price $1,349.02 a month. Self-pay pen $349 to $399 through Novo Nordisk. As little as $25 with commercial insurance and the savings card[4][5] | List price $1,086.37 a month. Self-pay KwikPen $299 to $699 by dose through Lilly, vial from $299. As little as $25 with commercial insurance and the savings card[6][7] |
This comparison is for education only and is not medical advice. Wegovy and Zepbound are prescription medicines with distinct FDA-approved indications. Whether either is appropriate for you, and at what dose, is a decision for a licensed clinician.
Is Zepbound the same as Wegovy?
No. Wegovy acts on one gut-hormone receptor, GLP-1. Zepbound acts on two, GIP and GLP-1. Beyond weight management, Wegovy is approved to lower heart attack and stroke risk in adults with heart disease and excess weight, and for the liver disease MASH. It is also approved for children 12 and older with obesity, and it now comes as a daily tablet as well as a weekly shot. Zepbound is approved for moderate to severe obstructive sleep apnea in adults with obesity.[2][3]
Which works better for weight loss, Wegovy or Zepbound?
Tirzepatide, the drug in Zepbound, did better in the one trial that compared them. SURMOUNT-5 gave 751 adults with obesity and no diabetes the highest dose they tolerated for 72 weeks. Weight fell 20.2% with tirzepatide and 13.7% with semaglutide, and waist size fell 18.4 cm versus 13.0 cm. The trial was open-label and funded by Eli Lilly. It used semaglutide up to 2.4 mg, not the 7.2 mg Wegovy dose approved later. The Wegovy weight loss calculator and the Zepbound weight loss calculator chart average loss week by week from trial data.[1][2]
Which has more side effects, Wegovy or Zepbound?
In SURMOUNT-5, stomach and gut side effects were the most common in both groups. Most were mild to moderate and showed up while the dose was going up. In each drug's own placebo-controlled trials, nausea was reported by 44% of adults on Wegovy 2.4 mg and 25% to 29% on Zepbound 5 mg to 15 mg. Those were separate trials, so the rates are not a head-to-head result. Both labels carry a boxed warning about thyroid C-cell tumors.[1][2][3]
| Side effect | Wegovy 2.4 mg | Zepbound 5 mg to 15 mg |
|---|---|---|
| Nausea | 44% | 25% to 29% |
| Diarrhea | 30% | 19% to 23% |
| Vomiting | 24% | 8% to 13% |
| Constipation | 24% | 11% to 17% |
| Abdominal pain | 20% | 9% to 10% |
Why are people stopping Wegovy?
In Wegovy's trials, 6.8% of adults on the 2.4 mg dose stopped for good because of side effects, versus 3.2% on placebo. In Zepbound's two main trials, 4.8% to 6.7% stopped because of side effects, versus 3.4% on placebo, most of them in the first few months. The labels do not track people who stop over price or coverage.[2][3]
Why do people switch from Wegovy to Zepbound?
The labels do not say why people switch, and neither gives a conversion between them. The one direct comparison is SURMOUNT-5, where weight fell 20.2% on tirzepatide and 13.7% on semaglutide at 72 weeks. Zepbound starts at 2.5 mg a week for 4 weeks and steps up by 2.5 mg after at least 4 weeks at each dose. Its label asks people on birth control pills to switch to a non-oral method or add a barrier method for 4 weeks after starting and after each dose increase. A prescriber decides whether and how to switch.[1][3]
Which costs more, Wegovy or Zepbound?
At list price, Wegovy is $1,349.02 a month and Zepbound is $1,086.37. Paying cash through the makers, Wegovy pens cost $349 a month at most doses. Zepbound KwikPens cost $299 at 2.5 mg, $399 at 5 mg, and $499 to $699 at higher doses. From 7.5 mg up, a first purchase or a refill within 45 days costs $449. With commercial insurance that covers the drug, each savings card can bring a fill to as little as $25. Under the Medicare GLP-1 Bridge, eligible members pay $50 a month for Wegovy and no more than $50 a month for Zepbound.[4][5][6][7]
Prices checked October 3, 2026.
| Monthly price | Wegovy | Zepbound |
|---|---|---|
| List price | $1,349.02 | $1,086.37 |
| Self-pay through the maker | $349 for 0.25 mg through 2.4 mg. $399 for 7.2 mg | $299 for 2.5 mg, as a KwikPen or vial. KwikPen prices are $399 for 5 mg, $499 for 7.5 mg, and $699 for 10 mg, 12.5 mg, or 15 mg. A $449 price applies to 7.5 mg through 15 mg KwikPens on a first purchase and on refills within 45 days |
| Commercial insurance with the savings card | As little as $25 | As little as $25 |
| Medicare GLP-1 Bridge | $50 | No more than $50 |
Can you take Wegovy and Zepbound together?
Both labels say no. The Wegovy label says it is not recommended with any other GLP-1 receptor agonist. The Zepbound label says it is not recommended with any GLP-1 receptor agonist or other tirzepatide product.[2][3]
Does Zepbound have semaglutide in it?
No. The only active ingredient in Zepbound is tirzepatide, the same drug as Mounjaro. Semaglutide is the active ingredient in Wegovy and Ozempic. Compare Wegovy vs Mounjaro, Mounjaro vs Zepbound, or the two drugs themselves in semaglutide vs tirzepatide.[3][2]
- Aronne LJ et al. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity. N Engl J Med 2025;393:26-36 (SURMOUNT-5) (NEJM)
- FDA label, Wegovy (semaglutide) injection and tablets, Novo Nordisk (DailyMed)
- FDA label, Zepbound (tirzepatide) injection, Eli Lilly (DailyMed)
- Wegovy list price (wholesale acquisition cost), Novo Nordisk Pricing, March 2026 (Novo Nordisk)
- Wegovy cost and coverage: savings card, self-pay prices, and the Medicare GLP-1 Bridge, read October 3, 2026 (Novo Nordisk)
- Zepbound list price and self-pay prices, Lilly pricing information, read October 3, 2026 (Eli Lilly)
- Zepbound savings card, self-pay offers, and the Medicare GLP-1 Bridge, read October 3, 2026 (Eli Lilly)